Claire Friedman on Immunotherapy in Elderly Patients With Melanoma

Video

Claire Friedman, MD, Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy for elderly patients with melanoma.

Claire Friedman, MD, Memorial Sloan Kettering Cancer Center, discusses the promise of immunotherapy for elderly patients with melanoma.

A study was conducted at MSK that observed patients aged 80 or older who were treated with ipilimumab (Yervoy), pembrolizumab (Keytruda), nivolumab (Opdivo), or a combination of ipilimumab and nivolumab, between 2008 and 2015. The results, Friedman said, were very exciting, particularly for patients on ipilimumab, who had the best long-term survival data, with about 25% still alive today.

The study also revealed a plateau in the overall survival cure for elderly patients with melanoma, who traditionally had a poor prognosis.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.